Leana Wen Warns Wellness Peptide Craze Sidesteps Clinical Trials

Washington Post opinion columnist Dr. Leana S. Wen — a physician and former Baltimore health commissioner — published a pointed warning on May 28 arguing that the exploding “wellness” peptide market has replaced the rigor of clinical trials with unfettered self-experimentation.

In her piece, titled “Beware the risks of ‘wellness’ peptides,” Wen writes that over the past two years she has increasingly fielded questions from readers, patients, and colleagues about peptides promoted on social media and sold by med spas and wellness clinics. Her concern centers on a fundamental mismatch: patients are injecting compounds that have never undergone FDA safety and efficacy review, often based on anecdotal claims amplified by influencers.

The Core Argument: Marketing Without Evidence

“These are not supplements,” Wen writes. “They are biologically active substances — short chains of amino acids that can trigger real physiological effects. The question is whether we know what those effects are, and for most wellness peptides, the answer is no.”

Wen’s column zeroes in on the marketing gap: clinics present peptides as cutting-edge wellness tools, she argues, without disclosing that none of the most popular compounds — BPC-157, TB-500, GHK-Cu, and others — have received FDA approval for the purposes for which they are being prescribed. The FDA’s July 2026 PCAC meeting could reshape the regulatory landscape, but for now, Wen contends, patients are making decisions without adequate information.

“Choice implies informed consent,” Wen writes. “When patients are told peptides can help with recovery, aging, and inflammation without being told that the evidence base is thin and the long-term risks unknown, that is not informed consent — it is marketing.”

Joining a Growing Chorus of Safety Warnings

The Washington Post column arrives amid a surge of mainstream media coverage on peptide safety. It joins recent warnings from the Lancet, ECRI and ISMP, and CBS News medical correspondent Dr. Celine Gounder, who told viewers this week that some health officials are now telling medical professionals to stop prescribing certain peptides.

A separate audit released May 26 by MDConsultingNY found that peptide therapy websites promote benefits nearly four times more often than they disclose safety details. The 100-page review across 25 states showed that benefit language appeared on 100% of reviewed pages while average presence of core safety signals — FDA status, product sourcing, and risk discussion — was just 26.5%.

The Compounding Pharmacy Angle

Wen’s opinion piece also highlights the role of compounding pharmacies, which can legally produce copies of FDA-approved drugs when there is a documented medical need but cannot manufacture copycat versions of unapproved peptides for general wellness use. Wen notes that some pharmacies are pushing into this gray area, creating a regulatory challenge that the FDA has been slow to address.

This concern tracks with the FDA’s ongoing enforcement actions. In recent months, the agency has intensified compounding pharmacy oversight, signaling that the window for unregulated peptide compounding may be narrowing.

A Credible Voice Enters the Debate

The column is notable for coming from a physician with public health credentials rather than a medical board or government agency. Wen served as Baltimore’s health commissioner during the 2015 opioid epidemic and has been a prominent voice on evidence-based medicine. Her entry into the peptide debate signals that the conversation is moving beyond regulatory circles into the broader public health establishment.

Her Washington Post platform amplifies the message to a national audience. Forbes previously reported on the mainstreaming of peptide therapy, while the Lancet has warned that the peptide craze is outpacing regulation.

What Comes Next

The FDA’s advisory committee meeting in July will consider whether to recommend enforcement discretion for several popular peptides, a decision that could either legitimize part of the current market or reinforce existing restrictions. Meanwhile, the number of published articles on peptide safety in major outlets has more than doubled since April 2026, reflecting growing mainstream awareness.

As Wen puts it: “The question is not whether peptides can be beneficial — some almost certainly are, and legitimate research should continue. The question is whether we are building a system where safety data precedes use, or one where millions of people become unwitting test subjects.”

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.

{
  "@context": "https://schema.org",
  "@type": "NewsArticle",
  "headline": "Leana Wen Warns Wellness Peptide Craze Sidesteps Clinical Trials",
  "description": "Washington Post columnist Leana Wen warns the peptide craze replaces clinical trials with self-experimentation, as med spas market unapproved compounds without safety details.",
  "datePublished": "2026-05-29",
  "author": {
    "@type": "Organization",
    "name": "PeptidesBeat Staff"
  }
}